2027 ICD-10-CM Diagnosis Code F16.180Hallucinogen abuse with hallucinogen-induced anxiety disorder
ICD-10-CM Codes›F01–F99›F10-F19›F16
- Billable — Valid for Submission
- Risk Adjusts — HCC 137
- Chronic Condition
F16.180 is a billable ICD-10-CM diagnosis code for hallucinogen abuse with hallucinogen-induced anxiety disorder. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 894 through 897. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Anxiety and fear-related disorders and Hallucinogen-related disorders.
For Medicare Advantage risk adjustment, F16.180 maps to CMS-HCC Category 137 (Drug Use Disorder, Moderate/Severe, or Drug Use with Non-Psychotic Complications) under the V28 model, adding a risk factor of about 0.424 for a community, non-dual, aged beneficiary in payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
F16.180 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to F16.180: its own notes plus those printed at F16.1, F16, and Chapter 5. A note printed at a category, block or chapter applies to every code under it.
Includes
Further defines, or gives examples of, the content of the category.
- ecstasy
- PCP
- phencyclidine
- disorders of psychological development
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
Excludes2
Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name F16.180, its category, or a range that includes it.
Excludes1 2
These codes carry an Excludes1 note naming F16.180: they are not reported together with it, unless the two conditions are unrelated.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Disorder (of) See Also: Disease;
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Patient EducationClinical
Anxiety
Anxiety is a feeling of fear, dread, and uneasiness. It might cause you to sweat, feel restless and tense, and have a rapid heartbeat. It can be a normal reaction to stress. For example, you might feel anxious when faced with a difficult problem at work, before taking a test, or before making an important decision.
The full article covers:
- What is anxiety?
- What are anxiety disorders?
- What are the types of anxiety disorders?
- What causes anxiety disorders?
- Who is at risk for anxiety disorders?
- What are the symptoms of anxiety disorders?
- How are anxiety disorders diagnosed?
- What are the treatments for anxiety disorders?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert F16.180 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About F16.180Overview
What is the ICD-10 code for hallucinogen abuse with hallucinogen-induced anxiety disorder?
The ICD-10-CM code for hallucinogen abuse with hallucinogen-induced anxiety disorder is F16.180 (sometimes written as F16180). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is F16.180 (Hallucinogen abuse with other hallucinogen-induced disorder) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report hallucinogen abuse with hallucinogen-induced anxiety disorder on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does F16.180 group to?
When hallucinogen abuse with hallucinogen-induced anxiety disorder is the principal diagnosis on an inpatient stay, it groups to MS-DRG 894, 897, 895, 896, with relative weights from 0.6272 to 1.6610 depending on complications. Higher weights mean higher Medicare reimbursement.
Can F16.180 be reported with a code from F16.2?
Not as a rule. The Excludes1 note at F16.1, which applies to F16.180, lists "hallucinogen dependence (F16.2-)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).
What is the ICD-9 equivalent of F16.180?
Under the General Equivalence Mappings, hallucinogen abuse with hallucinogen-induced anxiety disorder converts to ICD-9-CM 292.89 (drug mental disorder NEC). The mapping is approximate, so confirm the match fits the documentation.
What HCC is F16.180?
F16.180 (hallucinogen abuse with hallucinogen-induced anxiety disorder) maps to CMS-HCC Category 137 (Drug Use Disorder, Moderate/Severe, or Drug Use with Non-Psychotic Complications), commonly written as HCC 137, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 55 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. It does not map to any RxHCC in the Part D prescription drug model.
Does F16.180 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, F16.180 adds a risk adjustment factor of about 0.424 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.297 to 0.502 depending on the payment segment). A more severe related category (HCC 135 and HCC 136) supersedes it when both are reported. See the full factor table on the HCC 137 category page.
